Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma … Read more
Celltrion Inc (068270) - Total Liabilities
Latest total liabilities as of September 2025: ₩4.24 Trillion KRW
Based on the latest financial reports, Celltrion Inc (068270) has total liabilities worth ₩4.24 Trillion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Celltrion Inc - Total Liabilities Trend (2007–2024)
This chart illustrates how Celltrion Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Celltrion Inc Competitors by Total Liabilities
The table below lists competitors of Celltrion Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WuXi AppTec Co. Ltd
PINK:WUXIF
|
USA | $23.12 Billion |
|
Shanghai Pudong Development Bank Co Ltd
SHG:600000
|
China | CN¥9.05 Trillion |
|
Anhui Conch Cement Co Ltd
PINK:AHCHY
|
USA | $51.94 Billion |
|
Coca-Cola European Partners PLC
NASDAQ:CCEP
|
USA | $23.28 Billion |
|
Telus Corp
NYSE:TU
|
USA | $43.03 Billion |
|
NetApp Inc
NASDAQ:NTAP
|
USA | $8.64 Billion |
|
Bank Central Asia Tbk
JK:BBCA
|
Indonesia | Rp1242.32 Trillion |
|
Li Auto Inc
NASDAQ:LI
|
USA | $79.92 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Celltrion Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celltrion Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celltrion Inc (2007–2024)
The table below shows the annual total liabilities of Celltrion Inc from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩3.48 Trillion | +24.48% |
| 2023-12-31 | ₩2.79 Trillion | +72.60% |
| 2022-12-31 | ₩1.62 Trillion | -0.39% |
| 2021-12-31 | ₩1.62 Trillion | +1.96% |
| 2020-12-31 | ₩1.59 Trillion | +61.40% |
| 2019-12-31 | ₩986.73 Billion | +8.69% |
| 2018-12-31 | ₩907.85 Billion | +2.74% |
| 2017-12-31 | ₩883.60 Billion | +7.37% |
| 2016-12-31 | ₩822.97 Billion | -12.30% |
| 2015-12-31 | ₩938.39 Billion | -3.72% |
| 2014-12-31 | ₩974.60 Billion | +9.34% |
| 2013-12-31 | ₩891.38 Billion | +30.55% |
| 2012-12-31 | ₩682.77 Billion | +34.46% |
| 2011-12-31 | ₩507.77 Billion | +35.20% |
| 2010-12-31 | ₩375.57 Billion | +37.31% |
| 2009-12-31 | ₩273.53 Billion | -2.15% |
| 2008-12-31 | ₩279.55 Billion | +701.67% |
| 2007-12-31 | ₩34.87 Billion | -- |